Clinical trial
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of…
NCT00151450 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00151450 |
|---|---|
| Title | Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder |
| Official title | An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety |
| Intervention type | Drug |
| Interventions | Pregabalin, Venlafaxine XR |
| Enrollment | 390 |
| Start date | Mar 1, 2005 |
| Completion | Nov 1, 2006 |
| First posted | Sep 9, 2005 |
| Last update posted | Jan 22, 2021 |
| Countries | Belgium, Canada, France, Ireland, Italy, Netherlands, Spain, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: